BenzingaDoubao · 实盘不做把握 5/10不做原因:SAME_DAY_TICKER_DUPLICATE
北京时间·🕒 发布 13:11:36·⟳ 抓取 13:13:48 +2m12s·⚡ 决策 10-14 13:18:09 +4m21s·13.3 天前
Liquidia与United Therapeutics达成全球和解：支付3.807亿美元了结全部诉讼、放弃YUTREPIA的PH-ILD适应症，盘后暴涨约42%
过去24小时同一标的已存在入场，抑制重复下注：LQDA.US
📄 原文Benzinga↗ 原文
Liquidia Corporation (NASDAQ:LQDA) shares jumped 42.48% to $38.20 after the bell on Tuesday after the company announced…
不做 United Therapeutics Corporation（UTHR.US）
3.807亿美元分期收款相对233亿市值仅约1.6%，盘后+0.3%已显示无重定价；PH-ILD竞品退出属预期内（9/30已胜诉并涨过），无新增edge，多空均不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
LQDA以3.807亿美元买断全部诉讼、放弃PH-ILD但保住年销售近9亿美元量级的PAH核心业务，破产/禁令尾部风险出清；夜盘+48%后股价仍较9/30败诉前低约37%，估值修复或未走完，但只在回踩时小仓参与。UTHR收款占市值约1.6%且股价无反应，不交易。
消息传播链
- 公司宣布全球和解：净付3.807亿美元、移除PH-ILD标签、PAH连续供应，了结全部六项诉讼；通稿为首发一手来源
- 2026-10-13 16:00-20:00 ET市场反应Futu行情（NASDAQ盘后/夜盘）LQDA盘后放量约483万股、+42.48%收38.20美元，盘中区间26.35–42.04；夜盘续升至约39.7(+48%)，UTHR盘后仅+0.3%市场反应:LQDA +42%~48%，UTHR约持平
关键理由
- 9/30败诉令LQDA单日-57%、20日累计-59%，定价了禁令与不确定性；和解把全部损失封顶在3.807亿美元（现金3.961亿+单季销售2.227亿美元可覆盖），PAH销售与供应明确不中断，是确定性的尾部风险出清
- 即使夜盘+48%至约39.7美元，仍较败诉前约63美元低约37%，而PH-ILD之外的PAH核心价值被Q3 2.227亿美元净销售验证，后续研报重估与空头回补可能继续推动修复
主要风险
- 盘后已涨42-48%且盘后区间高达26.35–42.04美元，10月14日开盘可能高开低走、见光死，故放弃追开盘、只挂回踩单
- PH-ILD适应症永久移除、3.807亿美元现金流出可能引发再融资稀释；若公司后续披露资金缺口或分析师重估PAH价值低于当前价格则逻辑证伪，立即离场
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-14 · 影响 weakens
媒体复述集中于‘付费结束专利战、PAH供应得到保障’，未发现公司否认、和解生变或资金链断裂报道；但3.807亿现金支出接近账面3.961亿现金，存在后续融资稀释担忧，构成降仓依据而非否决
检索:Liquidia settlement dilution cash payment analyst downgrade PH-ILD removal reaction 原文 ↗ - 做多前查反向 · 来源 futu · 日期 2026-10-13 · 影响 weakens
盘后区间26.35-42.04美元、收盘38.20低于夜盘39.7，首小时分歧极大；夜盘成交量仅约9万股（占盘后约2%），夜盘价位代表性弱，追开盘风险高
检索:LQDA盘后量价 高开低走 见光死
先例如何影响了这次决策
对本次决策的影响:因干净对齐先例不足，仓位压至probe、放弃开盘市价追高、改用回踩限价并放宽时间止损至5日以等待研报重估
方向:本轮检索到Moderna-Roivant/Arbutus 22.5亿美元专利和解（2026-03-04，收款方大涨）、Axsome SUNOSI和解（2026-06-04）等同类方向，但仅见聚合站转载，未在本轮取得公司IR/通稿首发锚点，不满足首发与时刻校验，未纳入定量统计
涨幅量级:不使用外部先例定幅度；改以同一标的自身价格结构校准：9/30败诉单日-57.19%为跌幅上限，和解仅恢复非PH-ILD部分且有3.807亿代价，修复目标取跌幅回收的保守一段
形态:专利败诉后以现金和解换取核心适应症继续销售，历史同类（如仿制药专利和解）首日多为高开高走伴剧烈波动，但样本锚不干净不做定量依赖
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`liquidia united therapeutics settlement litigation yutrepia treprostinil | liquidia yutrepia label change ph-ild removal delaware ruling | lqda uthr global settlement ph-ild patent`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 447 ms
{ - stock_quote 成功 stock_tools HTTP · 258 ms
{ - web_search 成功 doubao_search · 1,399 ms
豆包搜索结果（原始查询:Liquidia United Therapeutics global settlement YUTREPIA PH-ILD announcement October 13 2026；API SearchType:web） - web_search 成功 doubao_search · 1,545 ms
豆包搜索结果（原始查询:biotech stock surges settlement patent litigation after adverse ruling removes injunction overhang examples Amarin Vascepa；API SearchType:web） - web_search 成功 doubao_search · 1,319 ms
豆包搜索结果（原始查询:Liquidia September 30 2026 Delaware ruling 327 patent stock reaction United Therapeutics win；API SearchType:web）
原文全文
展开原文 · 2,507 字
Liquidia Corporation (NASDAQ:LQDA) shares jumped 42.48% to $38.20 after the bell on Tuesday after the company announced a global settlement with Maryland-based biotechnology and pharmaceutical company United Therapeutics Corporation (NASDAQ:UTHR) that resolves all pending litigation.
Patent Ruling Forces Label Change
According to Liquidia, a biopharmaceutical company based in North Carolina, the settlement follows a Sept. 30 ruling by the U.S. District Court for the District of Delaware. The court found that UTHR’s patent claims were valid and infringed by Liquidia. The claims cover inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia agreed not to appeal and filed to remove the PH-ILD indication from YUTREPIA’s label. The settlement includes mutual releases and is not an admission of liability by either party.
YUTREPIA, an inhaled dry-powder form of treprostinil approved in 2025, will continue to be available to patients with pulmonary arterial hypertension (PAH) without interruption, the company said. PAH is a rare, progressive disease with no cure that affects about 45,000 diagnosed patients in the U.S.
Sales and Cash to Fund Payouts
Liquidia will pay UTHR a net $175 million within 30 business days, plus $145.4 million in two $72.7 million installments due Jan. 31 and Apr. 30, 2027. It will also pay $60.3 million this month to resolve antitrust-related interests.
Chief Operating Officer and Chief Financial Officer Michael Kaseta said, "We expect to fund the outlined payments from the ongoing sales of YUTREPIA and cash on hand."
Preliminary, unaudited third-quarter YUTREPIA net product sales were $222.7 million. Cash and equivalents totaled $396.1 million as of Sept. 30.
Trading Metrics, Technical Analysis
| Metric | Liquidia | United Therapeutics |
|---|---|---|
| Market Capitalization | $2.40 billion | $23.31 billion |
| Annual Trading Range | $21.94–$93.61 | $409.15–$609.35 |
| 1-Year Gain | 17.74% | 25.32% |
LQDA has a Relative Strength Index (RSI) of 22.47.
Price Action: According to Benzinga Pro data, the Liquidia stock closed the regular session at $26.81, down 3.11%.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Jirapong Manustrong / Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Patent Ruling Forces Label Change
According to Liquidia, a biopharmaceutical company based in North Carolina, the settlement follows a Sept. 30 ruling by the U.S. District Court for the District of Delaware. The court found that UTHR’s patent claims were valid and infringed by Liquidia. The claims cover inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia agreed not to appeal and filed to remove the PH-ILD indication from YUTREPIA’s label. The settlement includes mutual releases and is not an admission of liability by either party.
YUTREPIA, an inhaled dry-powder form of treprostinil approved in 2025, will continue to be available to patients with pulmonary arterial hypertension (PAH) without interruption, the company said. PAH is a rare, progressive disease with no cure that affects about 45,000 diagnosed patients in the U.S.
Sales and Cash to Fund Payouts
Liquidia will pay UTHR a net $175 million within 30 business days, plus $145.4 million in two $72.7 million installments due Jan. 31 and Apr. 30, 2027. It will also pay $60.3 million this month to resolve antitrust-related interests.
Chief Operating Officer and Chief Financial Officer Michael Kaseta said, "We expect to fund the outlined payments from the ongoing sales of YUTREPIA and cash on hand."
Preliminary, unaudited third-quarter YUTREPIA net product sales were $222.7 million. Cash and equivalents totaled $396.1 million as of Sept. 30.
Trading Metrics, Technical Analysis
| Metric | Liquidia | United Therapeutics |
|---|---|---|
| Market Capitalization | $2.40 billion | $23.31 billion |
| Annual Trading Range | $21.94–$93.61 | $409.15–$609.35 |
| 1-Year Gain | 17.74% | 25.32% |
LQDA has a Relative Strength Index (RSI) of 22.47.
Price Action: According to Benzinga Pro data, the Liquidia stock closed the regular session at $26.81, down 3.11%.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Jirapong Manustrong / Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a3dd1f6a69· 2026-10-14 13:18 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前